Overview:
KRAS mutations are among the most common oncogenic drivers in solid tumors, particularly in non–small cell lung cancer, colorectal cancer pancreatic ductal adenocarcinoma, and several gynecologic malignancies. Recent advances in KRAS-targeted therapies have transformed the treatment landscape, yet clinicians face ongoing challenges in interpreting biomarker results, understanding the clinical relevance of specific KRAS variants, and integrating rapidly evolving efficacy and safety data into patient care.
To address these educational needs, this Oncology Town Hall™
will highlight key KRAS-related data presented at the 2026 ASCO Annual Meeting.
Using a dynamic format that combines abstract presentations with expert faculty
discussion, the program will place emerging evidence into clinical context and
explore its practical implications for treatment selection, toxicity
management, and multidisciplinary care across multiple KRAS-mutated solid
tumors. This approach will help clinicians translate new research findings into
evidence-based strategies that can improve patient outcomes in everyday
practice.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Evaluate the role of KRAS/RAS mutations across solid tumors and their implications for biomarker testing.
- Assess efficacy and safety profiles of approved and emerging KRAS/RAS-targeted therapies in solid tumors.
- Implement evidence-based strategies to prevent, monitor, and manage adverse events associated with KRAS/RAS-targeted therapies.
Target Audience:
This educational activity is directed toward academic and community-based oncologists, pathologists, advanced practice providers, oncology nurses, and other health care providers involved in the treatment of patients with KRAS/RAS-mutated cancers.
